Old dogmas and new perspectives in antibiotic-associated diarrhea;Altes und neues zur antibiotikaassoziierten diarrhö

Medizinische Klinik

Volumn 103, Issue 5, 2008, Pages 325-338

  Cramer, Jakob P ^a   Burchard, Gerd D ^b   Lohse, Ansgar W ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NONE

Author keywords

Antibiotic associated diarrhea; Clostridium difficile; Pseudomembranous colitis

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CLARITHROMYCIN; CLINDAMYCIN; COLESTYRAMINE; COTRIMOXAZOLE; IMMUNOGLOBULIN; MACROLIDE; METRONIDAZOLE; MEZLOCILLIN; NITAZOXANIDE; PIPERACILLIN; RIFAXIMIN; SULFONAMIDE; TETRACYCLINE; TINIDAZOLE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE; COMBINATION CHEMOTHERAPY; DIARRHEA; GERMANY; HEALTH CARE COST; HUMAN; IATROGENIC DISEASE; INCIDENCE; INTESTINE FLORA; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PROPHYLAXIS; PSEUDOMEMBRANOUS COLITIS; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; INTESTINAL MUCOSA; RECURRENCE; RISK FACTORS;

CLOSTRIDIUM DIFFICILE;

EID: 44349179731     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-008-1040-0     Document Type: Review

References (67)

1. McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 1998;16:292-307.
2. Wistrom J, Norrby SR, Myhre EB, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001;47:43-50.
3. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334-9.
4. Guarner F. Enteric flora in health and disease. Digestion 2006;73:Suppl 1:5-12.
5. Giulieri S, Mombelli G. Antibiotika-assoziierte Diarrhö. Schweiz Med Forum 2005;5:409-13.
6. Hove H, Tvede M, Mortensen PB. Antibiotic-associated diarrhoea, Clostridium difficile, and short-chain fatty acids. Scand J Gastroenterol 1996;31:688-93.
7. Hurley BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 2002;162:2177-84.
8. Grossman RF. The relationship of absorption characteristics and gastrointestinal side effects of oral antimicrobial agents. Clin Ther 1991;13:189-93.
9. Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis 1992;15:573-81.
10. Surawicz CM. Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials? Chemotherapy 2005;51:Suppl 1:81-9.
11. Gravet A, Rondeau M, Harf-Monteil C, et al. Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-lukD. J Clin Microbiol 1999;37:4012-9.
12. Asha NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol 2006;44:2785-91.
13. Modi N, Wilcox MH. Evidence for antibiotic induced Clostridium perfringens diarrhoea. J Clin Pathol 2001;54:748-51.
14. Benoit R, Dorval D, Loulergue J, et al. Post-antibiotic diarrheas: role of Klebsiella oxytoca. Gastroenterol Clin Biol 1992;16:860-4.
15. Hogenauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006;355:2418-26.
16. Krause R, Reisinger EC. Candida and antibiotic-associated diarrhoea. Clin Microbiol Infect 2005;11:1-2.
17. Aronsson B, Mollby R, Nord CE. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. J Infect Dis 1985;151:476-81.
18. Bouza E, Munoz P, Alonso R. Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect 2005;11:Suppl 4:57-64.
19. Bartlett JG, Onderdonk AB, Cisneros RL, et al. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 1977;136:701-5.
20. Rifkin GD, Fekety FR, Silva J Jr. Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin. Lancet 1977;2:1103-6.
21. Tedesco F, Markham R, Gurwith M, et al. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 1978;2:226-8.
22. Bartlett JG, Moon N, Chang TW, et al. Role of Clostridium difficile in antibiotic-associated pseudo membranous colitis. Gastroenterology 1978;75:778-82.
23. Larson HE, Price AB, Honour P, et al. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1978;1:1063-6.
24. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62.
25. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-84.
26. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005;18:247-63.
27. Alonso R, Martin A, Pelaez T, et al. Toxigenic status of Clostridium difficile in a large Spanish teaching hospital. J Med Microbiol 2005;54:159-62.
28. Barbut F, Gariazzo B, Bonne L, et al. Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004. Infect Control Hosp Epidemiol 2007;28:131-9.
29. Zaiß NH, Weile J, Ackermann G, et al. A case of Clostridium difficile-associated disease due to the highly virulent clone of Clostridium difficile PCR ribotype 027, March 2007 in Germany. Euro Surveill 2007;12:E071115.1.
30. Kleinkauf N, Weiss B, Jansen A, et al. Confirmed cases and report of clusters of severe infections due to Clostridium difficile PCR ribotype 027 in Germany. Euro Surveill 2007;12:E071115.2.
31. Vonberg RP, Schwab F, Gastmeier P. Clostridium difficile in discharged inpatients, Germany. Emerg Infect Dis 2007;13:179-80.
32. Reichardt C, Chaberny IF, Kola A, et al. Dramatic increase of Clostridium difficile-associated diarrhea in Germany: has the new strain PCR-ribotype 027 already reached us? Dtsch Med Wochenschr 2007;132:223-8.
33. McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204-10.
34. Samore MH. Epidemiology of nosocomial Clostridium difficile infection. Compr Ther 1993;19:151-6.
35. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40:1-15.
36. Raveh D, Rabinowitz B, Breuer GS, et al. Risk factors for Clostridium difficile toxin-positive nosocomial diarrhoea. Int J Antimicrob Agents 2006;28:231-7.
37. Lee KS, Shin WG, Jang MK, et al. Who are susceptible to pseudomembranous colitis among patients with presumed antibiotic-associated diarrhea? Dis Colon Rectum 2006;49:1552-8.
38. Peled N, Pitlik S, Samra Z, et al. Predicting Clostridium difficile toxin in hospitalized patients with antibiotic-associated diarrhea. Infect Control Hosp Epidemiol 2007;28:377-81.
39. Moshkowitz M, Ben-Baruch E, Kline Z, et al. Risk factors for severity and relapse of pseudomembranous colitis in an elderly population. Colorectal Dis 2007;9:173-7.
40. Teare JP, Booth JC, Brown JL, et al. Pseudomembranous colitis following clarithromycin therapy. Eur J Gastroenterol Hepatol 1995;7:275-7.
41. Nawaz A, Mohammed I, Ahsan K, et al. Clostridium difficile colitis associated with treatment of Helicobacter pylori infection. Am J Gastroenterol 1998;93:1175-6.
42. Gordin F, Gibert C, Schmidt ME. Clostridium difficile colitis associated with trimethoprim-sulfamethoxazole given as prophylaxis for Pneumocystis carinii pneumonia. Am J Med 1994;96:94-5.
43. Golledge CL, Riley TV. Clostridium difficile-associated diarrhoea after doxycycline malaria prophylaxis. Lancet 1995;345:1377-8.
44. Wilcox MH, Freeman J, Fawley W, et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother 2004;54:168-72.
45. Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother 1998;41:Suppl C:21-7.
46. McCusker ME, Harris AD, Perencevich E, et al. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003;9:730-3.
47. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-60.
48. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38:640-5.
49. Dhalla IA, Mamdani MM, Simor AE, et al. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antimicrob Agents Chemother 2006;50:3216-9.
50. Drudy D, Quinn T, O'Mahony R, et al. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 2006;58:1264-7.
51. Bauer TM, Lalvani A, Fehrenbach J, et al. Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than Clostridium difficile in hospitalized adults. JAMA 2001;285:313-9.
52. Mohan SS, McDermott BP, Parchuri S, et al. Lack of value of repeat stool testing for Clostridium difficile toxin. Am J Med 2006;119:356.e7-8.
53. Van den Berg RJ, Vaessen N, Endtz HP, et al. Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea in a prospective multicentre study. J Med Microbiol 2007;56:36-42.
54. Alonso R, Gros S, Pelaez T, et al. Molecular analysis of relapse vs re-infection in HIV-positive patients suffering from recurrent Clostridium difficile associated diarrhoea. J Hosp Infect 2001;48:86-92.
55. Jodlowski TZ, Oehler R, Kam LW, et al. Emerging therapies in the treatment of Clostridium difficile-associated disease. Ann Pharmacother 2006;40:2164-9.
56. Jokipii AM, Jokipii L. Comparative activity of metronidazole and tinidazole against Clostridium difficile and Peptostreptococcus anaerobius. Antimicrob Agents Chemother 1987;31:183-6.
57. Fung HB, Doan TL. Tinidazole: a nitroimidazole antiprotozoal agent. Clin Ther 2005;27:1859-84.
58. Musher DM, Logan N, Mehendiratta V, et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007;59:705-10.
59. Marchese A, Salerno A, Pesce A, et al. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 2000;46:253-66.
60. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846-8.
61. Pepin J. Improving the treatment of Clostridium difficile-associated disease: where should we start? Clin Infect Dis 2006;43:553-5.
62. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357:189-93.
63. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005;128:764-70.
64. Sazawal S, Hiremath G, Dhingra U, et al. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis 2006;6:374-82.
65. Dendukuri N, Costa V, McGregor M, et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005;173:167-70.
66. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006;101:812-22.
67. Johnston BC, Supina AL, Ospina M, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2007;2:CD004827.